Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Disease
- Delivery
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 97208
License Grant
The parties have formed a transformational alliance for the development and commercialization of RNAi therapeutics as genetic medicines. The parties have formed this new alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. Licensor will retain product rights in North America and Western Europe, while Licensee will obtain the right to access Licensor’s current 5×15 1 and future genetic medicines pipeline in the rest of the world (ROW), including global product rights for certain programs.
Upon the closing of the transaction, Licensee will opt-in to patisiran (ALN-TTR02) – an RNAi therapeutic currently in a Phase 3 trial for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) patients with Familial Amyloidotic Polyneuropathy – for its ROW territories, while Licensor retains full product rights in North America and Western Europe. The parties have also agreed to expand their current collaboration on ALN-TTRsc – an RNAi therapeutic currently in a Phase 2 trial for the treatment of ATTR patients with TTR amyloid cardiomyopathy – where the parties will co-develop and co-promote ALN-TTRsc in North America and Western Europe; Licensor will maintain development and commercialization control with ALN-TTRsc and Licensee will develop and commercialize the product in its ROW territories.
Field of Use
This agreement pertains to the drug industry relating to the field of Genetic Medicines for treatment of hemophilia and other rare bleeding disorders and for the treatment of hepatic porphyrias.
IPSCIO Record ID: 233131
License Grant
The parties revise the terms and conditions of the 2014 Licensee collaboration to (i) provide us the exclusive right to pursue the further global development and commercialization of all TTR products, including patisiran, ALN-TTRsc02 and any back-up products, (ii) provide Licensee the exclusive right to pursue the further global development and commercialization of fitusiran and any back-up products and (iii) terminate the previous co-development and co-commercialization rights related to revusiran, ALN-TTRsc02 and fitusiran under the 2014 Licensee collaboration.
License Property
RNAi therapeutics targeting transthyretin (TTR)
TTR products, including patisiran, ALN-TTRsc02 and any back-up products, referred to as the Exclusive TTR License, and the ALN-AT3 Global License.
The products are investigational RNAi therapeutics and are focused in three Strategic Therapeutic Areas, or “STArs†Genetic Medicines; Cardio-Metabolic Diseases; and Hepatic Infectious Diseases.
Fitusiran is an investigational RNAi therapeutic in development for the treatment of hemophilia A and B with or without inhibitors. The Fitusiran clinical development program is for the treatment of hemophilia and other rare bleeding disorder.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 255741
License Grant
The Licensee and the UK Licensor entered into a Settlement and License Agreement. The Agreement includes the grant from Licensor to the Licensee of a non-exclusive, global, irrevocable license, with the right to sublicense to affiliates and additional licensees, to all relevant patents for all current and future products of the Licensee, whether commercialized by the Licensee or a collaborator or licensee (including without limitation ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in the Licnesees current and future pipeline). Such license is fully paid up with no milestones or royalties, except for the limited royalty on ONPATTRO net sales in the European Union only.
License Property
ONPATTROâ„¢ is a medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
Onpattro is designed to interfere with RNA production of an abnormal form of the protein transthyretin (TTR). By preventing the production of TTR, the drug is intended to help reduce the accumulation of amyloid deposits in peripheral nerves, improving symptoms and helping patients better manage their polyneuropathy.
Field of Use
Hereditary transthyretin-mediated amyloidosis is a fatal rare disease. Familial amyloid polyneuropathy (FAP), also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis abbreviated also as ATTR (hereditary form), or Corino de Andrade's disease, is an autosomal dominant neurodegenerative disease.
IPSCIO Record ID: 219860
License Grant
The Collaboration Amendment, together with the AT3 License Terms and the Exclusive TTR License, revise the terms and conditions of the Master Agreement to (i) provide the Company the exclusive right to pursue the further global development and commercialization of all TTR products, including ALN-TTR02 (patisiran), ALN-TTRsc02 and any back-up products, (ii) provide Genzyme the exclusive right to pursue the further global development and commercialization of ALN-AT3 (fitusiran) and any back-up products and (iii) terminate the previous co-development and co-commercialization rights related to ALN-TTRsc, ALN-TTRsc02 and ALN-AT3 (fitusiran) under the Master Agreement.
License Property
With respect to all TTR products, including ALN-TTR02 (patisiran), ALN-TTRsc02 (a subcutaneously administered investigational RNAi therapeutic in clinical development) and any back-up products.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 277007
License Grant
The Canadian Licensor granted a license to develop and commercialize products with our lipid nanoparticle technology.
License Property
The product is ONPATTROâ„¢ (Patisiran/ALN-TTR02), an RNA interference therapeutic drug.
Field of Use
ONPATTROâ„¢ (patisiran) is for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Hereditary transthyretin-mediated amyloidosis is a genetic, life-threatening disease that is marked by abnormal buildup of the transthyretin protein in peripheral nerves, the heart and elsewhere in the body.
hATTR amyloidosis is a rare, inherited, rapidly progressive and life-threatening disease with a constellation of manifestations. In addition to polyneuropathy, hATTR amyloidosis can lead to other significant disabilities including decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
